Jonathan Dworkin, PhD, professor of microbiology & immunology at the Vagelos College of Physicians and Surgeons, has been named a fellow of the American Association for the Advancement of Science.
New details about the way this important molecule takes on tasks beyond sensing calcium could spur the develop of new drugs for breast cancer and other diseases.
BeatProfiler, a new research tool invented by Columbia bioengineers with the help of AI, speeds and simplifies the analysis of engineered heart tissue in the laboratory.
Several faculty members from the VP&S Department of Physiology & Cellular Biophysics gave presentations at the latest in the medical school’s Afternoon of Science series.
A new mouse model may be critical for understanding the most aggressive types of pancreatic cancer and finding ways to prevent its growth and recurrence.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
A newly developed prediction model may be able to calculate the risk of opioid relapse among individuals in the early stages of medication treatment—as early as three weeks into therapy.
As part of a new NIH consortium, scientists will trace how regions targeted by deep brain stimulation connect with the rest of the brain, information that could improve the treatment's efficacy.
With a transformational gift of $6.5 million, the Weinberg Family Cerebral Palsy Center at Columbia University will launch its second decade of excellence in clinical care, research, and education.
Columbia bioengineers are the first to program bacteria that guide immune cells to tumors, which could make more cancers treatable with immunotherapies.
In his new role leading the Chan Zuckerberg Biohub New York, Andrea Califano will bring together scientists from several universities to engineer the immune system to detect and treat disease.